Search News Archives
Special Offers and Promotions
Conferences | Events
Thermo Fisher Scientific Collaborates with ChromSword to Deliver Rapid Automated HPLC and UHPLC Method Development System
Thermo Fisher Scientific, the world leader in serving science, and ChromSword, a provider of innovative software products, have collaborated to launch an automated high performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) method development system that enables chromatographers to deliver robust and validated methods in less time and with higher confidence.
The new Thermo Scientific Vanquish Method Development HPLC and UHPLC system provides an integrated, network-deployable solution for automated method development and validation for diode-array, charged aerosol and mass spectrometric detection. Built for ease-of-use and speed, the system strategically combines the leading Vanquish HPLC and UHPLC systems and the Thermo Scientific Chromeleon Chromatography Data System (CDS) with ChromSwordAuto and ChromSword AutoRobust software. It leverages artificial intelligence to minimize manual interaction and enables method creation for complete compound detection with no prior sample knowledge required. Enhanced confidence is assured through multiple detection capabilities, and the integrated Chromeleon Data Vault further reinforces data integrity and compliance.
"Liquid chromatography method development is an incredibly time-consuming and labor-intensive process. To efficiently develop robust methods, frequent manual interactions and extensive method development experience are critical," said Christoph Nickel, senior director software marketing, Thermo Fisher Scientific. "The Vanquish Method Development HPLC and UHPLC system solves this challenge by allowing our customers to automate method development and validation, saving time and eliminating prerequisite expert user knowledge."
Dr. Sergey Galushko, head of research and development at ChromSword, said "Chromeleon CDS and ChromSwordAuto are two of the most powerful chromatography software systems available. By combining the intelligent method development capabilities of ChromSwordAuto with Chromeleon software’s flexible instrument control functionalities, we’re providing users with a complete suite of method development and validation tools. Through this package, a substantial reduction in method development time is possible for Chromeleon CDS users working with small and large molecules."
In addition to speed and ease-of-use, the system offers unparalleled method flexibility to pharmaceutical, biopharmaceutical, chemical and food testing laboratories, boasting automated column switching and universal analyte detection, with mass spectrometry-based peak tracking capabilities delivering more reliable results. Using Chromeleon CDS with ChromSwordAuto Chromeleon Connect and ChromSword AutoRobust Chromeleon Connect enables chromatographers to automate method development tasks, including method scouting, impurity profiling, fine optimization and method validation. Through next-generation automation, the system is well-placed to meet the changing needs of laboratories as they look to implement broader digitalization strategies and reduce on-site personnel.
For more information visit the Thermo Scientific Vanquish Method Development HPLC and UHPLC system webpage.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.